Clusterin facilitates COMMD1 and I-κB degradation to enhance NF-κB activity in prostate cancer cells

Secretory clusterin (sCLU) is a stress-activated, cytoprotective chaperone that confers broad-spectrum cancer treatment resistance and its targeted inhibitor (OGX-011) is currently in Phase II trials for prostate, lung, and breast cancer. However, molecular mechanisms by which sCLU inhibits treatmen...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Zoubeidi, Amina, Ettinger, Susan, Beraldi, Eliana, Hadaschik, Boris, Zardan, Anousheh, Klomp, Leo WJ, Nelson, Colleen C., Rennie, Paul S., Gleave, Martin E.
Formato: Artigo
Idioma:Inglês
Publicado em: 2010
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2808437/
https://ncbi.nlm.nih.gov/pubmed/20068069
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1541-7786.MCR-09-0277
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados